azelastine


Also found in: Dictionary, Wikipedia.
Related to azelastine: Azelastine hydrochloride

azelastine

 [ah-zel´as-tēn″]
an antihistamine used intranasally as the hydrochloride salt in treatment of hay fever and topically to the conjunctiva in treatment of allergic conjunctivitis.

azelastine

Astelin, Astepro, Optivar

Pharmacologic class: Histamine 1 (H1)-receptor antagonist

Therapeutic class: Respiratory inhalant, ophthalmologic agent

Pregnancy risk category C

Action

Selectively antagonizes H1 and inhibits release of histamine and other mediators from cells (such as mast cells) involved in allergic response. Based on in vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (such as leukotrienes and platelet-aggregating factor) has also been demonstrated. Decreased chemotaxis and activation of eosinophils has also been demonstrated.

Availability

Nasal spray (Astepro): 0.15% (205.5 mcg in each 0.137-ml spray)

Nasal spray, metered (Astelin): 137-mcg spray

Ophthalmic solution (Optivar): 0.05%

Indications and dosages

Seasonal and allergic rhinitis

Adults and children age 12 and older: 1 or 2 sprays (Astelin, Astepro) per nostril b.i.d. or 2 sprays (Astepro) per nostril once daily

Children ages 5 to 11: 1 spray (Astelin) per nostril b.i.d.

Perennial allergic rhinitis, vasomotor rhinitis

Adults and adolescents age 12 and older: 2 sprays (Astelin) per nostril b.i.d.

Allergic conjunctivitis

Adults and adolescents age 3 and older: 1 drop (Optivar) in each eye b.i.d.

Contraindications

• Hypersensitivity to drug or its components (Astelin, Optivar)

• None (Astepro)

Precautions

Use cautiously in:

• concurrent use of alcohol and CNS depressants (avoid Astepro use)

• pregnant or breastfeeding patients

• children (safety and efficacy not established for those younger than age 3 [Optivar]; age 5 [Astelin]; age 12 [Astepro]).

Administration

• Follow manufacturer's directions and prime Astelin nasal spray before use.

• Prime Astepro nasal spray before initial use and when it hasn't been used for 3 or more days.

• Be aware that patient shouldn't wear contact lenses when the eyes are red and that Optivar shouldn't be used to treat redness caused by contact lenses.

• Wait 10 minutes before allowing patient to put soft contact lenses back in after Optivar administration, because the preservative benzalkonium chloride may be absorbed.

Adverse reactions

CNS: dizziness (with Astelin); headache, fatigue, somnolence (with Astelin, Astepro)

EENT: transient eye burning or stinging (with Optivar); nasal burning, nasal discomfort, sneezing (with Astepro); pharyngitis, paroxysmal sneezing, rhinitis, epistaxis (with Astelin)

GI: nausea, dry mouth (with Astelin); nasal discomfort (with Astepro); epistaxis (with Astelin, Astepro)

Other: weight increase (with Astelin); bitter taste

Interactions

Drug-drug. Cimetidine: increased mean Cmax and area under the curve of orally administered azelastine

CNS depressants: additional decreased alertness and impairment of CNS performance (with Astelin, Astepro)

Drug-behaviors. Alcohol use: decreased alertness and impairment of CNS performance (with Astelin, Astepro)

Patient monitoring

• Monitor patient for bothersome adverse reactions.

Patient teaching

• Instruct patient on proper use of nasal spray and eyedrops.

• Advise patient to avoid other antihistamines, alcohol, and other CNS depressants such as sedatives while using nasal spray.

• Instruct patient to avoid spraying nasal spray into the eyes.

• Advise patient not to wear contact lenses if the eyes are red. Instruct the patient who wears soft contact lenses and whose eyes aren't red to wait at least 10 minutes after instilling eye-drops before inserting contact lenses.

• Caution patient to avoid driving and other hazardous activities until drug's effects on concentration and alertness are known.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

azelastine

An ANTIHISTAMINE drug used in the treatment of hay fever. Brand names are Optilast and Rhinolast.
References in periodicals archive ?
Ireland-based Perrigo Company has received final approval on its Abbreviated New Drug Application for azelastine hydrochloride nasal spray (0.15%) from the United States Food and Drug Administration, it was reported yesterday.
Sonnemann, "Nasal spray and eye drops containing ectoine, a novel natural, non-drug anti-allergic substance are not less effective than azelastine nasal spray and eye drops in improving the symptoms of allergic rhinitis and conjunctivitis," in Proceedings of the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI '11), 2011.
Scoparone (purity 98%, HPLC), azelastine, anti-dinitrophenyl (DNP) IgE, DNP-human serum albumin (HSA) and HEPES were purchased from Sigma-Aldrich Chemical Co.
The least-used drugs were the bronchodilator montelukast (12 [5.4%]) and the nasal antihistamine azelastine (17 [7.7%]).
Azelastine (Astelin) is the only intranasal antihistamine currently approved in the United States.
Azelastine Hcl 140 meg and Fluticasone furoate 27.5 meg per dose (Nasal Spray)
M2 EQUITYBITES-May 14, 2014-Perrigo Company receives approval for azelastine hydrochloride nasal spray from US Food and Drug Administration
It is indicated for patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
Dymista (MP29-02) is a novel formulation of azelastine hydrochloride and fluticasone propionate.
The second-generation agents--fexofenadine, loratadine, cetirizine, and azelastine were developed in recent years to reduce these side effects.
Intranasal azelastine, an [H.sub.1] antihistamine, is FDA-approved for the treatment el' vasomotor rhinitis as well as seasonal allergic rhinitis (LOE: 1).
SEATTLE -- The approval of intranasal azelastine spray by the Food and Drug Administration offers patients with perennial nonallergic rhinitis an effective alternative to intranasal steroids, according to two studies presented at the annual meeting of the American College of Allergy, Asthma, and Immunology.